As expected, the 2020 presidential campaign season has evolved into a post-election battle consisting of legal challenges in crucial battleground states as President Trump’s campaign attempts to prevent the counting of ballots they allege are or could be invalid.
— FOX News
New commitment-free ‘try and buy’ model allows businesses to swiftly adopt or expand unattended automation
and simplify the purchasing decision process
HOBOKEN, N.J.–(BUSINESS WIRE)–Organizations globally have been impacted by dynamic changes in recent months and are in critical need of efficiencies in delivering the service their customers demand at the rapid pace and excellent quality they expect. To answer this need, NICE (Nasdaq: NICE) today announced a new commercial offer, named ‘The Easiest Decision You’ll Make This Year’, providing unattended RPA robots at no cost or commitment for a two-year period, to help organizations quickly power their business with the benefits RPA offers. Its strong financial standing and innovation-driven portfolio place NICE in a unique position to bring this commercial RPA offer to market. This opportunity allows organizations to quickly adopt or expand process automations across their business to improve efficiencies, increase productivity, and drive service excellence even with a remote workforce and while keeping the cost of ownership low. Click here to learn more.
The advantages offered by RPA to the bottom line are widely accepted around the world. In today’s post-pandemic environment where organizations are struggling to address business-critical operational and service-related challenges, RPA offers a lifeline that enables organizations to overcome them. Fabrizio Biscotti, Research Vice President at Gartner confirms this in his report, “Forecast Analysis: Robotic Process Automation, Worldwide.” In a press release discussing the report, he stated “The key driver for RPA projects is their ability to improve process quality, speed and productivity, each of which is increasingly important as organizations try to meet the demands of cost reduction during COVID-19. Enterprises can quickly make headway on their digital optimization initiatives by investing in RPA software, and the trend isn’t going away anytime soon.”
The new commercial offer by NICE provides unattended robots at no charge or commitment for a period of two years. Organizations can choose to continue for a third year at a significant discount on robot pricing. By removing license costs from the equation, businesses can easily take the decision to adopt RPA now or scale automation across more areas of the business, gaining the benefits at a low total cost of ownership (TCO).
Barry Cooper, NICE Enterprise Group President, said, “This is a time when organizations are most in need of efficiency and ensuring service excellence not just because their business requires it but because their customers need it. Our strong financial position enables us to help businesses with their digital optimization initiatives and keep their operations on track during these challenging times. With this offer, organizations can power their business to provide better, faster service even as employees work remotely – without the risk or high costs.”
About NICE
NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.
Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.
Contacts
Corporate Media Contact
Christopher Irwin-Dudek, +1 201 561 4442, ET, chris.irwin-dudek@nice.com
Investors
Marty Cohen, +1 551 256 5354, ET, ir@nice.com
Yisca Erez +972 9 775 3798, CET, ir@nice.com
PITTSBURGH–(BUSINESS WIRE)–PPG (NYSE: PPG) today announced the appointment of Marvin Mendoza as global head of diversity, equity and inclusion (DE&I), effective Nov. 9, 2020. In this newly-developed role, Mendoza will be responsible for designing, leading and executing PPG’s global DE&I vision and strategy, and leveraging data-driven insights to accelerate the company’s DE&I agenda. Mendoza will report to Kevin Walling, PPG chief human resources officer.
“We have a responsibility as individuals and as an organization to ensure our workforce is inclusive of all backgrounds and reflects the communities in which we live and work,” said Walling. “At PPG, we know that a diverse workforce, representing wide-ranging nationalities, cultures, languages, religions, ethnicities, and professional and educational experiences, allows us to meet challenges quickly, creatively and effectively.”
Most recently, Mendoza served as diversity & inclusion (D&I) chief operating officer for PricewaterhouseCoopers (PwC), where he drove the development and execution of a firm-wide D&I vision, strategy and roadmap. In this role, Mendoza collaborated with the firm’s executive team to integrate D&I into business practices and processes. He also partnered with the human capital team to embed D&I across the talent lifecycle, enhancing the culture of belonging for all employees. Mendoza coached executives, employees, and clients on D&I, led the evolution of the firm’s D&I data and analytics approaches, and was at the helm of evolving the firm’s D&I strategy in response to the impacts of COVID-19 and racial injustice.
Prior to this position, Mendoza served in a variety of leadership roles that operated at the intersection of the workforce, business, and society. He served as the chief of staff for PwC’s “Workforce of the Future” practice, leading the launch and scaling of a $300 million business focused on helping clients address demographic and technological shifts disrupting workforces. While in this role, Marvin led PwC’s D&I consulting practice, helping clients across all industries and sectors reimagine and execute their D&I strategies. He has also served as the lead for PwC’s Purpose Activation consulting practice, as a program leader during large-scale global transformations, and as an international human resource policy and process consultant.
Mendoza holds a bachelor’s degree in International Business Administration from The College of New Jersey, Ewing, New Jersey.
To learn more about PPG’s commitment to DE&I, click here.
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and materials that our customers have trusted for more than 135 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.1 billion in 2019. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
We protect and beautify the world is a trademark and the PPG Logo is a registered trademark of PPG Industries Ohio, Inc.
CATEGORY Corporate
Contacts
PPG Media:
Mark Silvey
Corporate Communications
+ 1 412-434-3046
PPG Investors:
John Bruno
Investor Relations
+1-412-434-3466
Election night can be nerve-wrecking.
— FOX News
SHANGHAI & PRINCETON, N.J.–(BUSINESS WIRE)–LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients in China and major Asian markets, today announced that it has received clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the Phase 3 PROOF trial of infigratinib, a potential first-line treatment for patients with locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions. LianBio has in-licensed infigratinib from BridgeBio Pharma, Inc. and is responsible for the registration application, clinical development and future commercial operations of the product candidate in Mainland China, Hong Kong and Macau.
Infigratinib is an investigational innovative, oral, selective and potent inhibitor of fibroblast growth factor receptor (FGFR) 1-3 with well-defined novel chemical structures and pharmacological effects, currently under Phase 3 global development by BridgeBio. In a separate clinical trial investigating infigratinib for patients with FGFR2-fusion positive cholangiocarcinoma who had progressed on gemcitabine-based therapy, infigratinib demonstrated an overall response rate of 27% [1]. The Phase 3 PROOF trial is a multicenter, randomized and controlled study designed to evaluate the pharmacokinetic profile, efficacy, and safety of infigratinib in patients with locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions.
“This clearance by the China NMPA highlights the efficiency of LianBio’s operational model to bring cutting-edge technology to China,” said Dr. Bing Li, Chief Executive Officer of LianBio. “Untreated cholangiocarcinoma is usually fatal, with only 50% of patients surviving for one year. Given the severity of the disease and increasing prevalence in China, there is a high urgency to bring innovative treatments to this patient population. Supported by our partner BridgeBio, LianBio is well-positioned to advance the clinical development of this product candidate.”
Reference
About LianBio
LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. For more information, please visit lianbio.com.
Contacts
Investor:
Thomas Hoffmann
Solebury Trout
646-378-2931
Media:
Hannah Gendel
Solebury Trout
646-378-2943
As Election Day failed to produce a clear victor, investors waited and watched. Stock futures swung between gains and losses.
— NYT: Top Stories
Joe Biden expressed confidence to supporters, and President Trump falsely claimed victory. In Senate races, Democrats faced an uphill battle to claim a majority.
— NYT: Top Stories
The president made his unfounded claim even though no news organizations declared a winner between him and Joseph R. Biden Jr., and a number of closely contested states still had millions of mail-in ballots to count.
New York Times: Top Stories
Shana, a former Walmart employee, went viral on both TikTok and Twitter after she posted a video of herself publicly quitting and then storming out.
— FOX News
Regardless of the election results, President Trump will be the one directing the government’s coronavirus response as infections climb and winter approaches.
— New York Times: Top Stories